R&D at other companies
Segments
By segment
See fullOther financials
Where this comes from
Reported directly by Apogee Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Apogee Therapeutics, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Apogee Therapeutics, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Apogee Therapeutics, Inc.'s R&D?
- Apogee Therapeutics, Inc. (APGE) reported R&D of $60.82M in Q1 2026.
- How has Apogee Therapeutics, Inc.'s R&D changed year-over-year?
- Apogee Therapeutics, Inc.'s R&D increased by 31.1% year-over-year, from $46.39M to $60.82M.
- What is the long-term trend for Apogee Therapeutics, Inc.'s R&D?
- Over 2 years (2023 to 2025), Apogee Therapeutics, Inc.'s R&D has grown at a 77.1% compound annual growth rate (CAGR), from $68.42M to $214.71M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.